We’ve Been Shortlisted in the 2021 SelectScience Scientists' Choice Awards®

Laboratory scientists across the globe are invited to vote for their favorite clinical products of 2020. Here’s how.
We’ve Been Shortlisted in the 2021 SelectScience Scientists' Choice Awards®

The 2021 Scientists Choice Awards®

SelectScience’s annual Scientists' Choice Awards is celebrating its 14th anniversary by honoring the most innovative and effective technologies of the past year. The awards provide scientists worldwide with the opportunity to acknowledge the instruments, assays, tools, or consumables that have made the most difference to their work.

Thanks to our loyal customers, we’re delighted to announce the Access SARS-CoV-2 IgM assay > has been nominated in the Best New Clinical Assay/Kit of 2020 category.

Our high-sensitivity and high-specificity SARS-CoV-2 IgM assay > has market-leading accuracy with a high positive predictive value (PPV) and a high negative predictive value (NPV). This provides clinicians with useful immune response information and may help determine if their patients have had a recent COVID-19 infection.

Casting Your Vote

Voting closes Sunday, June 13, 2021. All scientists who cast their vote for their favorite clinical products of 2020 will be entered into a drawing for a chance to win a $500/£400/450 € Amazon Gift Card from SelectScience.

Interested in sharing your thoughts?

Editorial Team
Editorial Team
The Beckman Coulter editorial team brings you timely news and resources focused on elevating clinical laboratory performance and advancing patient care.

Related Articles

It’s Time to Be Seen: Re-architecting Healthcare for Women—And Why Everyone Gains

It’s Time to Be Seen: Re-architecting Healthcare for Women—And Why Everyone Gains

Women's health is often narrowly defined by reproductive care, overlooking critical issues like cardiovascular disease, infective endocarditis, heart failure, and mental health.
Advancing Clinical Capabilities to Empower Better Outcomes

Advancing Clinical Capabilities to Empower Better Outcomes

Discover how our philosophy of Advancing Clinical Capabilities is helping us deliver greater insights in areas like women’s health, cardiovascular disease, infectious disease, and beyond.
Rethinking Heart Failure Diagnosis in an Era of Rising Obesity

Rethinking Heart Failure Diagnosis in an Era of Rising Obesity

As obesity rates climb toward 50% of the U.S. population, clinicians face a growing diagnostic challenge: obesity is associated with lower NT-proBNP levels, potentially masking heart failure in the patients most at risk.